![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC in Combination and as a Single Agent
Mon, Mar 18
|Tuscan Kitchen
Verzenio is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer.
Time & Location
Mar 18, 2019, 5:30 PM
Tuscan Kitchen, 67 Main St, Salem, NH 03079, USA
About The Event
SPEAKER:
Yelena Novik, MD
Perlmutter Cancer Center
NYU Langone Health New York NY
Program Description:
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, I combination with an Al, and as a single agent for HR+, HER2- advanced or MBC. Information about mechanism of action and dosing will also be presented.
Program Objectives:
- Discuss the unmet needs for women with HER+, HER2- MBC
- Examine the efficacy and safety profile of Verzenio
- Review practical considerations for the use of Verzenio
RSVP to Aimee Ferry
Ferry_Aimee_R@lilly.com
(603) 475-4602